86results about How to "Stop progress" patented technology

The present invention generally relates to methods and devices for treatment of spinal deformity, and in particular to the utilization of at least one implant to either maintain the position of at least one vertebra of a patient to prevent increase in abnormal spinal curvature, to slow progression of abnormal curvature, or to impose at least one corrective displacement and/or rotation on at least one vertebra of a patient so as to incrementally correct abnormal spinal curvature.

Contact lenses and methods for preventing or slowing progression of myopia are described. The contact lenses include a vision correction area and a myopic defocus area. Various examples of the contact lenses are described. Methods include providing the present contact lenses, or applying one or more of the contact lenses to an eye or eyes of a person. The contact lenses and methods are particularly useful in children.

A formulation comprising an ophthalmically effective amount of one or more quinones of Formula I. Use of a formulation comprising one or more quinones of Formula I for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more quinones of Formula I is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more quinones of Formula I is also discussed.

The present invention provides novel biomaterials comprising one or more of Mg, Zn and F ions in a carbonate-containing biphasic calcium phosphate (BCP) system. The biomaterial may contain Mg, Zn, F, Mg and Zn, Mg and F, Zn and F, or Mg, Zn and F. The biomaterial may be substantially similar in composition to bone mineral (a carbonate apatite). The biomaterial may feature slow release of Mg, Zn, F, Ca, and P ions. The biphasic calcium phosphate, BCP, may be a mixture of unsubstituted hydroxyapatite (HA) and unsubstituted .-TCP, Ca₃(PO₄)₂. BCP of varying HA/.-TCP ratios may be produced by sintering calcium-deficient apatite, for instance having a Ca/P<1.5, 1.6, 1.67, 1.75 or 1.8 that has been prepared either by a precipitation or by a hydrolysis method or by a solid-state reaction. The amount of each component (by weight %) present in the biomaterials may be as follows: Mg 0.5 to 12 wt %, Zn 1 to 12 wt %, F 0.1 to 4 wt %, calcium 20 to 40 wt %, phosphate 10 to 20 wt %, and carbonate (CO₃) 1 to 20 wt %. The biomaterial may further comprise one or more other ion such as strontium, manganese, copper, boron or silicate, or one or more other organic moiety such as a protein, a peptide, or a nutraceutical which may provide antioxidant, anti-bacterial or anti-inflammatory properties. The invention also provides methods of inhibiting bone resorption, methods of treating osteoporosis or delaying the onset of osteoporosis, methods of treating a bone fracture, and methods of inhibiting osteoclast activity. Further, the invention provides methods of treating or reversing bone deficiencies such as bone loss, similar to osteoporosis, caused all or in part by a mineral deficient diet, a disease such as cancer or osteopenia, a treatment such as steroid therapy or radiation therapy, or a physical condition such as immobilization.

Different memory testing devices, systems, and methods for conducting memory tests, and for storing and displaying test data and trends are disclosed. The tests generally are based on generating a random sequence of signals, displaying the sequence to an examinee, the examinee memorizing the sequence, and inputting the sequence into the testing device. The signals could have visual, auditory, positional, and/or tactile components. The signals could also be alphanumeric strings.

The testing device measures test outcome variables, computes a composite memory score based on the test outcome variables, records and displays the stored test data. The testing device may also include a communication interface for periodically transferring the stored test data to a database residing on a remote server displaying the test data of the examinee on a website through an internet connection

The testing device need not be a physical device. Instead, it is possible to implement the functionality of the testing device in a virtual device which is basically a software application, installed and used on a personal computer, a mobile phone, a PDA, etc.

A scanning machine (10) includes a scan surface (12) for receiving a page or pages to be scanned. A motion detector (20) monitors the copy surface to detect movement of the pages. In response to detecting a cessation of motion on the scan surface, the motion detector generates a trigger signal which causes a capture circuit (30) to capture an image of a page on the scan surface. If, during the capture of the page image, the motion detector detects motion of the page, the motion detector generates an abort signal which terminates capture of the image and empties a buffer memory (32). Once cessation of motion of the page is again detected, another trigger signal is issued and another attempt is made to capture an image. In this manner, scanning is started and stopped by natural, simple gestures without the operator pushing buttons.

An open-close member control apparatus has a function to release a foreign matter pinched to an open-close member. The open-close member is either (i) driven only while a manipulation switch is manipulated or (ii) driven continuously once the manipulation switch is manipulated to a specified position regardless of whether the manipulation is then released. When trapping of a foreign matter is detected under an open movement of the open-close member to an open direction based on an open command signal from the manipulation switch, an electric power supply to a motor is restricted to stop a progress of the trapping. When receiving a close command signal from the manipulation switch after restricting the electric power supply, the electric power is supplied to the motor to drive the open-close member to a close direction under a restricted state of a predetermined operation.

A friction stabilizer having tabs comprising a tubular body comprising an exterior surface and having a first portion and having a second portion provided with a taper. The first portion has an impact end and the second portion has an insertion end. A tab is on the tubular body and extends outward from the exterior surface of the tubular body in a direction toward the impact end and away from the insertion end of the tubular body. The tabs can be rectangular shaped or triangular shaped or have other shapes which prevent the friction stabilizer from being removed from a drilled bore in a mine. When the friction stabilizer with tabs is inserted into a drilled bore in a mine, the tabs do not impede insertion. But, after insertion into the drilled bore the tabs resist removal of the tubular body, and thus allow the stabilizer to support the mine wall or ceiling. The friction stabilizer is made by taking a steel coil and punching the shape of the tabs in the metal, for example sheet metal, unrolled from the coil. A notch is also punched into the sheet at a predetermined location. Rolling die roll the tubular body, and a cutting machine cuts the tubular body at the notches, so tubular bodies of predetermined length are cut. The tabs extend from the exterior surface of the tubular body due to the natural spring constant of the steel or metal from which the tubular body is made. A weld ring is welded to the impact end and has a weld ring gap space. In another embodiment the tubular body has first portion, a second portion with a bent portion joining them together. An extendable tab is formed in the first portion proximal the bend portion and the extendable tab is diametrically opposite a tube gap space.

The present invention relates to soluble CD26 or a biologically active variant of the soluble CD26 that effectively inhibits angiogenesis and inflammation in a mammalian subject, pharmaceutical compositions comprising the soluble CD26 and the use of soluble CD26 in methods of treatment.

The invention provides a solid, self-bioadhesive composition for topical application that adheres to the oral mucosal tissue comprising a therapeutically effective amount of at least one herbal or homeopathic active agent; and a pharmaceutically acceptable solid bioadhesive carrier in an amount from about 40 to 99 percent based on the weight of the whole composition.

The present invention is a dual door release handle and related mechanisms for use with cabs of industrial vehicles that an operator may reach from outside of such a cab in order to fully release a door that has been propped open in order to close it. The dual door release handle of the present invention includes a latching mechanism having a handle mounted on the inside of the cab that extends into the doorway such that it may be reached through the open door of the cab by an operator who is located outside and/or below the cab. A linkage is provided between this handle and an operable device associated with the release mechanism inside the cab. The linkage is operatively attached to the handle and to the release mechanism such that turning the handle causes the linkage to move the release mechanism. Movement of the handle pulls the linkage and releases the holdback holding the open door against the side of the cab. Thus, an operator may reach up into the cab from the outside and pull down on the interior handle in order to release the door from its holdback position against the side of the cab allowing the door to swing freely so that it may be closed.

The present invention features systems, methods and devices directed to fire suppression and/or extinguishment using solid carbon dioxide and/or liquid or aqueous hydrogen. Systems and methods of deployment and/or dispersal of carbon dioxide and hydrogen (which would form water at its deployment location) are contemplated. The present invention also contemplates method(s) of fire suppression and/or extinguishment which may include the steps of: carbon dioxide canister deployment, formation of a carbon dioxide curtain and hydrogen deployment and/or dispersal.

The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma. The invention further concerns a second diagnostic method for glaucoma comprising the steps of a) providing an in vitro culture of cells; b) incubating a body fluid from a test individual with the in vitro culture of cells or incubating components, which are fractionated from the body fluid or from a body specimen of the test individual with the in vitro culture of cells; c) analyzing protein expression of the cells and/or analyzing the viability of the cells after treatment according to step b); and d) comparing the results of the analysis in step c) with standard data to determine a diagnostic result.

Three new safe pharmaceutical compositions in accordance with the present invention are for treatment and prevention of malignant pleural effusion and increase immune function comprise Lan Xiang Xi (LX) and polysaccharide of Dang Gui. Methods of treating and preventing cancer cells include inhibiting oncogenes, increasing activity of tumor suppressor, inducing differentiation of cancer cells, inhibiting cancer cells proliferation, inducing apoptosis of cancer cells, inhibiting growth of transplanted cancer and inhibiting cancer incidence, etc. In general, anticancer drug always decreases immune function. However, LX and LX+PDG can inhibit cancer also increase immune function at the same time. Also, LX and DG containing soybean-liposomes is safer than LX and DG.

Gene therapy compositions for the prevention and/or treatment of autoimmune diseases. The present invention relates to vectors, preferably plasmids that comprise specific promoters, that encode insulin-like growth factor I (IGF-I) or a functional biological equivalent thereof, which will be used to prevent or treat Type 1 Diabetes (DT1) and/or other autoimmune diseases. Moreover, the invention comprises the method of preventing or treating DT1 by means of the expression of IGF-I, or a functional biological equivalent thereof, in hepatic cells. IGF-I was capable of interrupting the immune attack against pancreatic β cells, thereby preventing the loss of β cell mass and, consequently, maintaining normal levels of circulating insulin.

A novel mechanical spark generating device for one-handed operation. The novel mechanical spark generating device includes a case having a case body and a relatively moveable striker arm extended therefrom, the case body includes a channel having an opening thereinto. A pyrophoric rod assembly is moveably carried in the channel of the case body, the pyrophoric rod assembly having a support surface adjacent to one end thereof, and a pyrophoric rod carried therein. A striker bar is fixed to the striker arm in a position for interacting with the pyrophoric rod of the pyrophoric rod assembly when the pyrophoric rod assembly is in a deployed configuration extended from the case body and the striker arm is moved there toward.

The invention relates to a method for improving the anticancer activity for Codonopsis lanceolata Benth.et Hook.F, which comprises: slicing or homogenizing fresh Codonopsis lanceolata Benth.et Hook.F, or crushing dry Codonopsis lanceolata Benth.et Hook.F, or powdering the dry Codonopsis Lanceolata Benth.et Hook.F; soaking in water; sterilizing under a high pressure; adding 0.5 to 5.0 percent of active yeast and 1 to 8 percent of glucose under a sterile condition when the temperature lowers to 30 DEG C; fermenting at 20 to 37 DEG C for 1 to 10 days, and adding a polar solvent after fermentation to extract for 5 to 24 hours at 0 to 100 DEG C; and filtering, recovering solvent and concentrating under reduced pressure or drying by freezing. The method can improve the inhibition effect of Codonopsis lanceolata Benth.et Hook.F on the growth of tumors.

The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and/or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount of preservatives such as benzalkonium chloride comparative to the conventional product and therefore, can reduce incidence of the adverse side effects caused by the preservatives. In addition, the composition of the present invention can be stored stably at room temperatures for a long term.